PMID- 22505551
OWN - NLM
STAT- MEDLINE
DCOM- 20120907
LR  - 20161018
IS  - 1437-4331 (Electronic)
IS  - 1434-6621 (Linking)
VI  - 50
IP  - 3
DP  - 2012 Feb 13
TI  - Effects of subcutaneous low molecular weight heparin and intravenous 
      unfractionated heparin on serum S100 concentrations in patients with 
      cerebrovascular diseases.
PG  - 525-8
LID - /j/cclm.2012.50.issue-3/cclm.2011.794/cclm.2011.794.xml [pii]
LID - 10.1515/cclm.2011.794 [doi]
AB  - BACKGROUND: S100 plays an important role in diagnosis and prognosis of acute 
      ischemic stroke. The objective was to investigate the effects of clinical 
      heparins administrations on serum S100 concentrations in patients with 
      cerebrovascular diseases. METHODS: Forty cases were enrolled in this study, 
      including 10 patients with percutaneous carotid intervention receiving 
      intravenous unfractionated heparin (UFH) at the beginning of stenting (group A1), 
      10 patients with carotid angiography receiving UFH-free therapy (group A2), 10 
      patients with cerebral infarction receiving subcutaneous low molecular weight 
      heparin (LMWH) anticoagulation therapy (group B1) and 10 patients with cerebral 
      infarction receiving LMWH-free therapy (group B2). S100 concentrations were 
      analyzed before and after heparin administrations. RESULTS: A rapid increase of 
      serum S100 (median, 1.74-fold, p<0.05) was observed in group A1 within 15 min of 
      UFH administration. In group B1, S100 significantly increased (median, 1.44-fold, 
      p<0.05) at 3 h after LMWH injection. CONCLUSIONS: Both intravenous UFH and 
      subcutaneous LMWH administration induced increases in serum S100 concentrations. 
      It should be taken into account when using S100 as a biomarker of cerebrovascular 
      diseases.
FAU - Wang, Shun
AU  - Wang S
AD  - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 
      Shandong, PR China.
FAU - Wang, Lili
AU  - Wang L
FAU - Zhang, Xin
AU  - Zhang X
FAU - Wang, Chuanxin
AU  - Wang C
FAU - Zheng, Guixi
AU  - Zheng G
FAU - Wu, Wei
AU  - Wu W
FAU - Zhang, Xuhua
AU  - Zhang X
FAU - Dong, Zhaogang
AU  - Dong Z
FAU - Du, Lutao
AU  - Du L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120213
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (S100 Proteins)
SB  - IM
MH  - Aged
MH  - Cerebrovascular Disorders/*blood
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/*pharmacology
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - S100 Proteins/*blood
MH  - Time Factors
EDAT- 2012/04/17 06:00
MHDA- 2012/09/08 06:00
CRDT- 2012/04/17 06:00
PHST- 2011/07/08 00:00 [received]
PHST- 2011/10/26 00:00 [accepted]
PHST- 2012/04/17 06:00 [entrez]
PHST- 2012/04/17 06:00 [pubmed]
PHST- 2012/09/08 06:00 [medline]
AID - /j/cclm.2012.50.issue-3/cclm.2011.794/cclm.2011.794.xml [pii]
AID - 10.1515/cclm.2011.794 [doi]
PST - epublish
SO  - Clin Chem Lab Med. 2012 Feb 13;50(3):525-8. doi: 10.1515/cclm.2011.794.